Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 May 16;29(18):2448–2458. doi: 10.1200/JCO.2010.30.3552

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2011 by American Society of Clinical Oncology

PMC Copyright notice

Fig 3. — Low levels of nuclear localized and tyrosine phosphorylated Stat5 (Nuc-pYStat5) predict increased risk of failure of antiestrogen therapy. (A-B) Low levels of Nuc-pYStat5 detected by diaminobenzidine chromogen immunohistochemistry (IHC) and pathologist scoring in patients treated with antiestrogen therapy (cohort IV) predicted (A) poor breast cancer-specific survival (CSS) and (B) reduced time to recurrence (TTR) of breast cancer. (C-D) Immunofluorescence and quantitative automated quantitative analysis of Nuc-pYStat5 expression in breast cancer patients treated with antiestrogen monotherapy (cohort V) revealed that low expression of Nuc-pYStat5 was predictive of (C) poor CSS and (D) reduced TTR of breast cancer. Kaplan-Meier plots with censored cases (+) and number of patients per group indicated.